KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBITDA: 2009-2024

Historic EBITDA for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $4.5 billion.

  • Regeneron Pharmaceuticals' EBITDA rose 0.39% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year decrease of 6.23%. This contributed to the annual value of $4.5 billion for FY2024, which is 9.10% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported EBITDA of $4.5 billion as of FY2024, which was up 9.10% from $4.1 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' 5-year EBITDA high stood at $8.0 billion for FY2021, and its period low was $3.5 billion during FY2020.
  • Over the past 3 years, Regeneron Pharmaceuticals' median EBITDA value was $4.1 billion (recorded in 2022), while the average stood at $4.2 billion.
  • In the last 5 years, Regeneron Pharmaceuticals' EBITDA skyrocketed by 127.74% in 2021 and then crashed by 48.55% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' EBITDA (Yearly) stood at $3.5 billion in 2020, then soared by 127.74% to $8.0 billion in 2021, then plummeted by 48.55% to $4.1 billion in 2022, then dropped by 0.35% to $4.1 billion in 2023, then climbed by 9.10% to $4.5 billion in 2024.